Search clinical trials for: Dipeptidyl peptidase-4 (DPP-4) inhibitors

Total 2581 results

Takeda

Completed

Study of Combination Therapy With SYR-322

Diabetes Mellitus

Japan
Novartis Pharmaceuticals

Completed

Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan (STEADFAST)

Type 2 Diabetes Mellitus

Egypt, United Kingdom, Turkey, Lebanon, Russian Federation, Tunisia, Malaysia, Germany, Spain, Saudi Arabia, Denmark, Indonesia, Jordan, Kuwait, Singapore, United Arab Emirates
Laval University
Merck Sharp & Dohme LLC

Completed

Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes

Diabetes Mellitus | Postprandial Lipemia

Canada
Zhejiang Cancer Hospital

Unknown

Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer (ACCN)

Neoadjuvant Therapy

China
The Leprosy Mission Nepal

Recruiting

CC-11050 Trial in Nepalese Patients With Erythema Nodosum Leprosum

Leprosy | Erythema Nodosum Leprosum

Nepal
Boehringer Ingelheim

Completed

An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

Carcinoma, Non-Small-Cell Lung

Spain, Israel, Italy, Austria, Czechia, Greece, Australia, Poland, Hungary, Portugal, Russian Federation
National Institute of Mental Health (NIMH)

Completed

Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients

Healthy | Major Depressive Disorder

United States
Robert Lowsky
National Cancer Institute (NCI)

Completed

A Phase I/II Study of Intratumoral Injection of SD-101

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Recurrent Small Lymphocytic...

United States
Horizon Pharma USA, Inc.

Completed

Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism

Aldehyde Dehydrogenase-2 (ALDH2) Deficiency

United States
Lexicon Pharmaceuticals

Completed

Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets

Healthy

United States
AstraZeneca

Completed

Drug Interaction Study - Effect of AZD5672 on the Pharmacokinetics of Digoxin

Healthy Volunteers | Pharmacokinetics

Germany
National Cancer Institute (NCI)

Completed

A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer

Prostate Cancer

United States
Bayer

Completed

Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors

Neoplasms

United States
University Hospital, Basel, Switzerland

Recruiting

Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects (2C-B)

Healthy

Switzerland
Actavis Inc.

Completed

Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions

Healthy

Canada
Jiangsu Simcere Pharmaceutical Co., Ltd.
Second Hospital of Shanxi Medical University

Completed

A Pilot Bioequivalence Study of Pomalidomide

Bioequivalence

China
Pfizer

Completed

Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Taiwan, Slovakia, Mexico, Canada, Hungary
Genuine Research Center, Egypt
Future Pharmaceuticals Industries, Egypt

Completed

Bioequivalence Study of Esomeprazole From Stomopral 40 mg Capsules Contain Enteric Coated Pellets (Future Pharmaceuticals Industries, Egypt) and Nexium 40 mg Delayed Release Capsules (AstraZeneca Sweden, Product of France)

Healthy

Egypt
Georgetown University
Genentech, Inc.; Melanoma Research Alliance

Terminated

The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma

Melanoma

United States
Bayer

Completed

Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma (SANE)

Carcinoma, Renal Cell

Russian Federation
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Takeda

Completed

Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects

Clinical Pharmacology

Japan
Novo Nordisk A/S

Completed

Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. (PIONEER 7)

Diabetes Mellitus, Type 2 | Diabetes

United States, Austria, Belgium, Norway, Turkey, Switzerland, Argentina, Korea, Republic of, Brazil, Egypt
Novo Nordisk A/S

Completed

Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes (PIONEER 3)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Israel, Japan, Russian Federation, United Kingdom, France, Mexico, South Africa, Turkey, Argentina, Germany, Romania, Brazil, Ukraine
AET Laboratories Private Limited

Completed

The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Assessed.

To Determine Bioequivalence Under Fed Conditions
National University of Malaysia

Completed

Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes Mellitus (GLP-1)

Type 2 Diabetes Mellitus | PreDiabetes

Malaysia
University of Pennsylvania
Children's Hospital of Philadelphia

Completed

Effect of Chronic Incretin-based Therapy in Cystic Fibrosis

Cystic Fibrosis | Pancreatic Insufficiency

United States
Dong-A ST Co., Ltd.

Completed

A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM

Diabetes Mellitus, Type 2

United States
Sherif S. Farag

Completed

Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Hematopoietic Stem Cell Transplantation | Graft vs Host Disease

United States
Novartis

Completed

Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)

Diabetes Mellitus, Type 2 | Renal Insufficiency

United States
Novartis Pharmaceuticals

Completed

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

Type II Diabetes

United States
Novartis

Completed

Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency

Diabetes Mellitus, Type 2

United States
Takeda

Completed

Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI"

Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution

Japan
Blandine Laferrere
Merck Sharp & Dohme LLC

Completed

Treatment of Diabetes After Gastric Bypass With Sitagliptin (LAF33)

Type 2 Diabetes Mellitus

United States
Kathleen Dungan

Terminated

Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery

Hyperglycemia | Diabetes Mellitus, Type 2

United States
University Health Network, Toronto
Merck Sharp & Dohme LLC

Completed

The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion (INDORSE)

Type 2 Diabetes

Canada
University of Missouri-Columbia

Terminated

Use of Sitagliptin to Decrease Microalbuminuria

Type 2 Diabetes | Microalbuminuria

United States
Long Min,MD

Unknown

Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic Ulcers (DPP4i)

Diabetic Foot Ulcer

China
Merck Sharp & Dohme LLC

Completed

ALPHA Sitagliptin Add on to Metformin (0431-103)

Diabetes Mellitus
Guangwei Li

Completed

Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics- the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics

Insulin Resistance | Insulin Secretion

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

Diabetes Mellitus, Type 2

Germany, Spain, United States, Canada, Taiwan, Korea, Republic of, Finland, Denmark, France, Japan, Philippines, Vietnam
Fourth People's Hospital of Shenyang

Completed

The Effect of Alogliptin on Pulmonary Function in Obese Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

Januvia Re-examination Study (MK-0431-181)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED)

Liver Insufficiency
AstraZeneca

Completed

Study of Multiple Doses of Saxagliptin (BMS-477118)

Type 2 Diabetes Mellitus
University of Padova

Completed

Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes

Type 2 Diabetes | Chronic Renal Failure

Italy
Boehringer Ingelheim

Completed

Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy Subjects

Hepatic Insufficiency
JW Pharmaceutical

Completed

Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone (CWP-DIANA-302)

Type 2 Diabetes Mellitus

Korea, Republic of

3

Subscribe